Drug Pricing

Pharma companies are starting to really come into their own with introducing innovative ways of pricing.
Alnylam only charges the $575k price for givosiran if the effect seen is on par with clinical trials.
Novartis now collects the $2.1m price tag for Zolgensma over 5 years.
Sanofi are offering $99/month subscriptions for insulin.
Pricing is a big issue for US Pharmaceuticals. There are start-ups looking at this issue as well – Generics 2.0.